KURA ONCOLOGY INC (KURA:NASDAQ)
$11.57 -0.52 (-4.3011%)
Analysed KURA ONCOLOGY INC (KURA:NASDAQ) News Sources
Kura Oncology CEO Buys 100,000 Shares for $1.2 Million. Does This Large Buy Bode Well for Shares in 2026?
25-08-2026
fool.com
The $1.24 Billion Reason Why Kura Oncology Stock Is Up Today
25-08-2026
barchart.com
KURA Stock Hits Fresh 52-Week High As CEO Buys More Shares — Retail Wonders If Wilson Is Following Moderna CEO’s Playbook
25-08-2026
stocktwits.com
Cancer Biotech Kura Oncology Rallies to New High After CEO’s Stock Purchase
27-08-2026
yahoo.com
Kura Oncology (KURA) Upgraded to Buy: What Does It Mean for the Stock?
31-08-2026
yahoo.com
Kura Oncology to Participate in Three Investor Conferences in September
01-09-2026
yahoo.com
Kura Oncology (KURA) Stock Looks Fully Priced After Its 56% Run
02-09-2026
yahoo.com
Kura Oncology Appoints Jennifer Fulk as Chief Financial Officer
08-09-2026
yahoo.com
Kura Oncology Launches Caspian Therapeutics with $50 Million Financing to Advance Menin Inhibition as a Potential Disease-Modifying Approach for Diabetes
09-09-2026
yahoo.com
Kura spins diabetes work into a Lilly-backed biotech startup
09-09-2026
biopharmadive.com
What is the current price of KURA ONCOLOGY INC (KURA:NASDAQ)?
The current price of KURA ONCOLOGY INC (KURA:NASDAQ) is $11.57.
KURA ONCOLOGY INC (KURA:NASDAQ) absolute price change since previous trading day?
The absolute price change of KURA ONCOLOGY INC (KURA:NASDAQ) since the previous trading day is $-0.52.
KURA ONCOLOGY INC (KURA:NASDAQ) percentage price change since previous trading day?
The percentage price change of KURA ONCOLOGY INC (KURA:NASDAQ) since the previous trading day is -4.3011%.
What is the most recent average sentiment score for KURA ONCOLOGY INC (KURA:NASDAQ)?
The most recent average sentiment score for KURA ONCOLOGY INC (KURA:NASDAQ) is 84 out of 100.
What is the most recent average sentiment for KURA ONCOLOGY INC (KURA:NASDAQ)?
The most recent sentiment for KURA ONCOLOGY INC (KURA:NASDAQ) is .
SEC-8K** Filing Available For KURA ONCOLOGY INC (KURA:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.